Dr. Reddy’s Voluntarily Recalls Five Lots of Ranitidine
Dr. Reddy's initiates voluntary recall of ranitidine due to microbial contamination.
The Indian pharmaceutical company Dr. Reddy’s Laboratories has initiated a voluntary recall of five lots of ranitidine hydrochloride tablets (150 mg, over-the-counter [OTC]) due to microbial contamination. The Class II recall was posted on FDA’s weekly enforcement report for Aug. 21, 2013 and initiated on Aug. 2, 2013. Ranitidine is used to treat gastroesophageal reflux disease.
The recall, which is nationwide in the United States, was due to microbial contamination of nonsterile products. A lot of raw material used in the manufacture of ranitidine was positive for Pseudomonas sp.
The ranitidine hydrochloride tablets, USP 150 mg, OTC, were distributed as Equate brand Maximum Strength Acid Reducer (65-count bottle), Equaline brand Maximum Strength Heartburn Relief, and Wal-Zan brand 150, Maximum Strength (24- count bottle) and distributed respectively by Wal-Mart Stores, Supervalu, and Walgreen Co.
The affected lots were: 5055822, expiration date 03/13; 5056317, expiration date 03/15; 5056507, expiration date 04/15; 7956571C, expiration date 4/15; and 7956572A, expiration date 04/15.
Source:
FDA
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
